Clinical Research Center of Alabama- Birmingham

Birmingham, Alabama 35244

0 studies enrolling now · 2 studies all time

What they study most

Atopic Dermatitis

Studies at this site

• Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) — Completed
• A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA) — Completed